According to Zhitong Finance App, Li's Pharmaceutical Factory (00950.HK) announced that on July 29, 2026, the Group's New Drug Clinical Trial (IND) application for ZK2401 in China was accepted by the China National Drug Administration (NMPA) Drug Evaluation Center. ZK2401 is a proprietary antibody drug conjugate (ADC) project independently developed by Lee's Pharmaceuticals. Lee's Pharmaceuticals owns the complete global intellectual property rights for this molecule.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.